当前位置: 首页 >> 检索结果
741. Dynamics of fat absorption and effect of sham feeding on postprandial lipema.
作者: Rosa N Chavez-Jauregui.;Richard D Mattes.;Elizabeth J Parks.
来源: Gastroenterology. 2010年139卷5期1538-48页
Given the importance of postprandial hyperlipidemia to increase risk for atherosclerosis, in the present study, stable isotope-labeled meals were fed to healthy subjects (7 males and 3 females) to investigate the kinetics chylomicron synthesis and the effect of sensory exposure to lipid on metabolism.
742. Study protocol: population screening for colorectal cancer by colonoscopy or CT colonography: a randomized controlled trial.
作者: Thomas R de Wijkerslooth.;Margriet C de Haan.;Esther M Stoop.;Marije Deutekom.;Paul Fockens.;Patrick M M Bossuyt.;Maarten Thomeer.;Marjolein van Ballegooijen.;Marie-Louise Essink-Bot.;Monique E van Leerdam.;Ernst J Kuipers.;Evelien Dekker.;Jaap Stoker.
来源: BMC Gastroenterol. 2010年10卷47页
Colorectal cancer (CRC) is the second most prevalent type of cancer in Europe. Early detection and removal of CRC or its precursor lesions by population screening can reduce mortality. Colonoscopy and computed tomography colonography (CT colonography) are highly accurate exams and screening options that examine the entire colon. The success of screening depends on the participation rate. We designed a randomized trial to compare the uptake, yield and costs of direct colonoscopy population screening, using either a telephone consultation or a consultation at the outpatient clinic, versus CT colonography first, with colonoscopy in CT colonography positives.
743. Surgical removal of omental fat does not improve insulin sensitivity and cardiovascular risk factors in obese adults.
作者: Elisa Fabbrini.;Robyn A Tamboli.;Faidon Magkos.;Pamela A Marks-Shulman.;Aaron W Eckhauser.;William O Richards.;Samuel Klein.;Naji N Abumrad.
来源: Gastroenterology. 2010年139卷2期448-55页
Visceral adipose tissue (VAT) is an important risk factor for the metabolic complications associated with obesity. Therefore, a reduction in VAT is considered an important target of obesity therapy. We evaluated whether reducing VAT mass by surgical removal of the omentum improves insulin sensitivity and metabolic function in obese patients.
744. Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.
作者: Ranjan Dohil.;Robert Newbury.;Lyman Fox.;John Bastian.;Seema Aceves.
来源: Gastroenterology. 2010年139卷2期418-29页
Eosinophilic esophagitis (EoE) is caused by immunologic reactions to ingested/inhaled allergens. The diagnosis is considered if >or=15 eosinophils per high-powered field (eos/hpf) are detected in mucosal biopsies. Placebo-controlled studies have not been conducted to evaluate the safety and efficacy of oral viscous budesonide (OVB).
745. Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease.
作者: Guy E Boeckxstaens.;Hanneke Beaumont.;Veerle Mertens.;Hans Denison.;Magnus Ruth.;John Adler.;Debra G Silberg.;Daniel Sifrim.
来源: Gastroenterology. 2010年139卷2期409-17页
Transient lower esophageal sphincter relaxations (TLESRs) are a major mechanism behind reflux. This study assessed the effects of lesogaberan (AZD3355), a novel gamma-aminobutyric acid type B receptor agonist, on reflux and lower esophageal sphincter (LES) function when used as add-on treatment in patients with reflux symptoms despite proton pump inhibitor (PPI) treatment.
746. Ribavirin improves early responses to peginterferon through improved interferon signaling.
作者: Jordan J Feld.;Glen A Lutchman.;Theo Heller.;Koji Hara.;Julie K Pfeiffer.;Richard D Leff.;Claudia Meek.;Maria Rivera.;Myung Ko.;Christopher Koh.;Yaron Rotman.;Marc G Ghany.;Vanessa Haynes-Williams.;Avidan U Neumann.;T Jake Liang.;Jay H Hoofnagle.
来源: Gastroenterology. 2010年139卷1期154-62.e4页
The therapeutic mechanisms of ribavirin for hepatitis C are unclear. Microarray analyses have shown that ribavirin increases induction of interferon-stimulated genes. We evaluated viral kinetics, serum cytokine expression, and viral mutagenesis during early stages of peginterferon therapy with and without ribavirin.
747. Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C.
作者: Robert J Fontana.;Arun J Sanyal.;Marc G Ghany.;William M Lee.;Andrea E Reid.;Deepa Naishadham.;Gregory T Everson.;Jeffrey A Kahn.;Adrian M Di Bisceglie.;Gyongyi Szabo.;Timothy R Morgan.;James E Everhart.; .
来源: Gastroenterology. 2010年138卷7期2321-31, 2331.e1-2页
We aimed to identify the incidence and predictors of de novo gastroesophageal variceal formation and progression in a large cohort of patients with chronic hepatitis C and advanced fibrosis.
748. Early laparoscopic cholecystectomy improves outcomes after endoscopic sphincterotomy for choledochocystolithiasis.
作者: Jan Siert K Reinders.;Annemarie Goud.;Robin Timmer.;Philip M Kruyt.;Ben J M Witteman.;Niels Smakman.;Ronald Breumelhof.;Sandra C Donkervoort.;Jeroen M Jansen.;Joos Heisterkamp.;Marina Grubben.;Bert van Ramshorst.;Djamila Boerma.
来源: Gastroenterology. 2010年138卷7期2315-20页
Patients with choledochocystolithiasis generally undergo endoscopic sphincterotomy (ES) followed by laparoscopic cholecystectomy (LC). However, many patients receive this surgery 6-8 weeks after ES. There is a high conversion rate of elective LC after ES, and patients can develop recurrent biliary events during the waiting period. We investigated whether the timing of surgery influences outcome.
749. Fibrin glue is effective healing perianal fistulas in patients with Crohn's disease.
作者: Jean-Charles Grimaud.;Nicolas Munoz-Bongrand.;Laurent Siproudhis.;Laurent Abramowitz.;Agnès Sénéjoux.;Véronique Vitton.;Luc Gambiez.;Bernard Flourié.;Xavier Hébuterne.;Edouard Louis.;Benoit Coffin.;Vincent De Parades.;Guillaume Savoye.;Jean-Claude Soulé.;Yoram Bouhnik.;Jean-Frédéric Colombel.;Jean-François Contou.;Yves François.;Jean-Yves Mary.;Marc Lémann.; .
来源: Gastroenterology. 2010年138卷7期2275-81, 2281.e1页
Fibrin glue is a therapeutic for fistulas that activates thrombin to form a fibrin clot, which mechanically seals the fistula tract. We assessed the efficacy and safety of a heterologous fibrin glue that was injected into the fistula tracts of patients with Crohn's disease (ClinicalTrials.gov No. NCT00723047).
750. Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial.
作者: Fabrizio Mecenate.;Adriano M Pellicelli.;Giuseppe Barbaro.;Mario Romano.;Angelo Barlattani.;Ettore Mazzoni.;Maria Elena Bonaventura.;Lorenzo Nosotti.;Pasquale Arcuri.;Antonio Picardi.;Giorgio Barbarini.;Cecilia D'Ambrosio.;Amerigo Paffetti.;Arnaldo Andreoli.;Fabrizio Soccorsi.; .
来源: BMC Gastroenterol. 2010年10卷21页
In patients with chronic hepatitis C virus (HCV) genotype 2 or 3, 24 weeks' treatment with pegylated interferon alfa (PEG-IFN-alpha) and ribavirin induces a sustained virological response (SVR) in almost 80% of cases. Evidence suggests that a similar response rate may be obtained with shorter treatment periods, especially in patients with a rapid virological response (RVR). The aim of this study was to compare the efficacy of 12 or 24 weeks of treatment in patients with chronic HCV genotype 2 or 3 and to identify patients suitable for 12 weeks treatment.
751. A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial.
作者: Solveig C Ligaarden.;Lars Axelsson.;Kristine Naterstad.;Stian Lydersen.;Per G Farup.
来源: BMC Gastroenterol. 2010年10卷16页
Some probiotics have shown efficacy for patients with irritable bowel syndrome (IBS). Lactobacillus (L.) plantarum MF1298 was found to have the best in vitro probiotic properties of 22 strains of lactobacilli. The aim of this study was to investigate the symptomatic effect of L. plantarum MF1298 in subjects with IBS. Primary outcome was treatment preference and secondary outcomes were number of weeks with satisfactory relief of symptoms and IBS sum score.
752. Does capsule endoscopy improve outcomes in obscure gastrointestinal bleeding? Randomized trial versus dedicated small bowel radiography.
作者: Loren Laine.;Amandeep Sahota.;Abbid Shah.
来源: Gastroenterology. 2010年138卷5期1673-1680.e1; quiz e11-2页
Capsule endoscopy improves the diagnostic yield in patients with obscure gastrointestinal (GI) bleeding, but whether it improves outcomes is uncertain.
753. Adjunctive functional pharyngeal electrical stimulation reverses swallowing disability after brain lesions.
作者: Vanoo Jayasekeran.;Salil Singh.;Pippa Tyrrell.;Emilia Michou.;Samantha Jefferson.;Satish Mistry.;Ed Gamble.;John Rothwell.;David Thompson.;Shaheen Hamdy.
来源: Gastroenterology. 2010年138卷5期1737-46页
Oropharyngeal dysphagia is an important disability that occurs after stroke; it contributes to aspiration pneumonia and death, and current modalities for rehabilitation of dysphagia have uncertain efficacy. We therefore examined the role of pharyngeal electrical stimulation (PES) in expediting human swallowing recovery after experimental (virtual) and actual (stroke) brain lesions.
754. Assessing factors influencing return back to work after cholecystectomy: a qualitative research.
作者: Frederik Keus.;Jolanda de Vries.;Hein G Gooszen.;Cornelis J H M van Laarhoven.
来源: BMC Gastroenterol. 2010年10卷12页
Cholecystectomy causes considerable financial burden on society with a major part caused by sick-leave. There are wide variations in duration of sick-leave. The aim of our study was to identify all aspects that influence the moment of return to work by using focus groups and to compare responses from patients and physicians.
755. Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis.
作者: Didier Lebrec.;Dominique Thabut.;Frederic Oberti.;Jean-Marc Perarnau.;Bertrand Condat.;Helene Barraud.;Faouzi Saliba.;Nicolas Carbonell.;Philippe Renard.;Marie-Jose Ramond.;Richard Moreau.;Thierry Poynard.; .
来源: Gastroenterology. 2010年138卷5期1755-62页
Pentoxifylline, an inhibitor of tumor necrosis factor-alpha, is given to patients with liver diseases, but its effects in patients with advanced cirrhosis are unknown. We performed a randomized, placebo-controlled, double-blind trial of its effects in patients with cirrhosis.
756. The potential therapeutic effect of melatonin in Gastro-Esophageal Reflux Disease.
作者: Tharwat S Kandil.;Amany A Mousa.;Ahmed A El-Gendy.;Amr M Abbas.
来源: BMC Gastroenterol. 2010年10卷7页
Gastro-Esophageal Reflux Disease (GERD) defined as a condition that develops when the reflux of stomach contents causes troublesome symptoms and/or complications. Many drugs are used for the treatment of GERD such as omeprazole (a proton pump inhibitor) which is a widely used antiulcer drug demonstrated to protect against esophageal mucosal injury. Melatonin has been found to protect the gastrointestinal mucosa from oxidative damage caused by reactive oxygen species in different experimental ulcer models. The aim of this study is to evaluate the role of exogenous melatonin in the treatment of reflux disease in humans either alone or in combination with omeprazole therapy.
757. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis.
作者: William J Sandborn.;Joshua Korzenik.;Bret Lashner.;Jonathan A Leighton.;Uma Mahadevan.;James F Marion.;Michael Safdi.;Charles A Sninsky.;Raman M Patel.;Keith A Friedenberg.;Preston Dunnmon.;David Ramsey.;Sunanda Kane.
来源: Gastroenterology. 2010年138卷4期1286-96, 1296.e1-3页
The practice of dosing mesalamines in divided doses for the treatment of ulcerative colitis (UC) began with sulfasalazine and was driven by sulfapyridine toxicity. This convention and the assumption that dosing multiple times a day is necessary to treat UC had not been challenged until recently. This study was conducted to determine the efficacy and safety of once-daily dosing of delayed-release mesalamine (Asacol 400-mg tablets) compared with twice-daily dosing for maintaining remission in UC patients.
758. Effects of ghrelin administration after total gastrectomy: a prospective, randomized, placebo-controlled phase II study.
作者: Shinichi Adachi.;Shuji Takiguchi.;Kazuyuki Okada.;Kazuyoshi Yamamoto.;Makoto Yamasaki.;Hiroshi Miyata.;Kiyokazu Nakajima.;Yoshiyuki Fujiwara.;Hiroshi Hosoda.;Kenji Kangawa.;Masaki Mori.;Yuichiro Doki.
来源: Gastroenterology. 2010年138卷4期1312-20页
Body weight (BW) loss and reduction of blood ghrelin level are commonly observed after total gastrectomy (TG). A prospective study was designed to elucidate whether exogenous ghrelin administration prevents postoperative BW loss by improving appetite and oral food intake in patients with gastric cancer after undergoing TG.
759. Efficacy of linaclotide for patients with chronic constipation.
作者: Anthony J Lembo.;Caroline B Kurtz.;James E Macdougall.;B J Lavins.;Mark G Currie.;Donald A Fitch.;Brenda I Jeglinski.;Jeffrey M Johnston.
来源: Gastroenterology. 2010年138卷3期886-95.e1页
Linaclotide is a minimally absorbed peptide agonist of the guanylate cyclase-C receptor that stimulates intestinal fluid secretion and transit and reduces pain in animal models. We assessed the safety and efficacy of a range of linaclotide doses in patients with chronic constipation.
760. Biofeedback is superior to electrogalvanic stimulation and massage for treatment of levator ani syndrome.
作者: Giuseppe Chiarioni.;Adriana Nardo.;Italo Vantini.;Antonella Romito.;William E Whitehead.
来源: Gastroenterology. 2010年138卷4期1321-9页
Levator ani syndrome (LAS) might be treated using biofeedback to teach pelvic floor relaxation, electrogalvanic stimulation (EGS), or massage of levator muscles. We performed a prospective, randomized controlled trial to compare the effectiveness of these techniques and assess physiologic mechanisms for treatment.
|